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Primary thyroid lymphomas (PTLs), although rare, must always be considered in the study of
thyroid masses, due to the specific diagnostic and therapeutic approach. The incidence of such
lymphomas is increasing, from 0,5% of the sixties (1) to 1-5% of all thyroid neoplasms today (2,
3). A Danish epidemiologic study reported an annual incidence of 2,1 cases per million (4). The
increase in incidence of such disease paralleled the increase of Hashimoto’s thyroiditis; such tight
correlation can be explained with the fact that thyroid lymphomas are more frequent in women,
(M/F ratio 2:1-14:1) (4, 5), the gender that presents the greater incidence of the Hashimoto’s thy-
roiditis. In 83% of patients with PTL coexists Hashimoto’s thyroiditis (6). In patients affected by
chronic autoimmune thyroiditis the probability of developing PTL is 20 times greater as compa-
red to general population (7); the longer duration of such autoimmune sickness correlates with
the increased risk of developing a PTL.
PLTs represent 2-7% of all extranodal primitive lumphomas (3, 8). Non-Hodgkin lymphoma
is the most common PLT (93%) (8), and is divided in two subtypes (4, 9): cellular B lymphoma
and cellular T lymphoma (6-27%) (10). The cellular B lymphoma group includes large type-hi-
gh grade lymphoma (very aggressive) and MALT lymphoma (low grade); large cell lymphomas
derive from transformation of MALT lymphomas (4, 9).
Various classifications have been proposed for such diseases, inducing much confusion in the
literature (11). According to the National Cancer Institute Working Formulation, about 70% of
PTLs are of intermediate grade (12-15). If Kiel’s classification is used, 65% are low grade, 30%
are high grade, and in 5% of cases grade is impossible to be defined (6).
Large B cell thyroid lymphomas present as an asymptomatic fast-growing mass; MALT
lymphomas instead grow slowly. PTLs generally infiltrate the surrounding structures, inducing
roughly in 25% of cases dysphagia, hoarseness or dyspnea (17). In 10-40% of cases hypothyroi-
dism occurs (12, 17), while hyperthyroidism is extremely rare (8,19). General symptoms associa-
ted with lymphomas, such as fever, excessive perspiration and weight-loss, are present in only 10-
20% of patients. Physical examination reveals a diffusely hypertrophic thyroid gland, fixed to sur-
rounding structures. In 40-50% of cases cervical lymphodenopathy coexists (11, 17).
Specific lab tests are lacking; in the majority of cases thyroid function values are altered (TSH
increase) due to hypothyroidism, together with autoimmune disease indicators (increase of an-
tithyreoglobulin and antiperoxidase antibodies) (11).
Radiologic studies and scintiscan are of fundamental importance in defining the extension of
disease, in planning therapy and in the differential diagnosis of the lymphoma from other thyroid
neoplasms or thyroiditis (21, 22). CT scan for lymphomas presents some peculiarities; it is impos-
sible anyway to reach the definitive diagnosis only with imaging (23) (Tab. 1). A characteristic fin-
ding at TC in thyroid lymphoma is the “donut sign”, caused by the tendency of the neoplasm to
encircle completely the trachea (22). Radioiodine scintiscan in not useful, as lymphocytes do not
have the capability of concentrating iodine. Gallium-67 instead highlights an uptake defect in 90%
of patients (24, 26). PET scan shows an aspecific uptake in Hashimoto’s thyroiditis and large cell
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B lymphoma (27, 28); such examination therefore is not useful in the diagnosis of PTL (29). On
the other hand, MALT lymphomas generally induce false negative results at PET (11).
Preoperative diagnosis of PTL may be reached during the workup of patients presenting with a
solitary thyroid nodule, a nodule in multinodular goiter, or a nodule in Hashimoto’s thyroiditis.
Preoperative diagnosis is often formulated at cytology on FNAB (Tab. 2): it is very easy in the ca-
se of large cell lymphomas (30-32). More complex is the definition of MALT lymphomas in pa-
tients affected by chronic autoimmune thyroiditis; in such cases immunohystochemical studies are
often necessary (33). Needle-biopsy is utilized only in rare cases, when FNAB is not diagnostic.
Once diagnosis is made, total body CT scan completes staging, according to Ann Arbor’s clas-
sification (Tab. 3). In about 50% of patients the disease is confined to the gland (stage IE), in
another 45% the gland and regional lymph nodes are involved (stage IIE); only 5% of cases show
lymph node involvement above and below the diaphragm (stage IIIE) or extranodal disease (sta-
ge IV) (4, 11, 34-36).
PTLs are easily curable if diagnosed early and correctly treated. At present no significative advan-
tage in survival has been demonstrated in patients at IE-IIE stage submitted to radical surgery (37-
39); some surgeons never take the surgical option in consideration in presence of PTL (40). Others
propose treating only stage IE with total thyroidectomy followed by radiotherapy, but preoperati-
vely it is very difficult to individuate the cases presenting thyroid capsule invasion (41, 42). The be-
st results after thyroidectomy have been obtained in the treatment of MALT lymphomas (43).
Thyroidectomy performed in patients affected by lymphoma presents a higher incidence of
complications if compared to procedures carried out for goiter or differentiated neoplasms; the
reason is the important pericapsular edema that hampers the correct individuation of anatomical
structures. In such cases the most frequent complications are bleeding, parathyroid ablation and
recurrent laryngeal nerve injury (44). If the procedure is performed by a dedicated surgeon the
complication rate does not change significantly in the different clinical settings (45).
According to the National Comprehensive Cancer Network (NCCN) Guidelines surgery em-
bodies only one of the therapeutic options for stage IE, and does not afford a better prognosis if
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TABLE 1 - CT FINDINGS IN THYROID NEOPLASMS.
Calcification Necrosis Local Invasion
Papillary carcinoma +/- +++/- --/+
Follicular carcinoma ---/+ -----/+ --/+
Medullary carcinoma +/- ----/+ --/+
Anaplastic carcinoma +++/- +++/- +++/-
Lymphoma -----/+ -----/+ +/-
TABLE 2 - CYTOLOGIC DIAGNOSIS OF PTLS BY FNAB.
Diagnosis by FNAB
Cha, 2002 (30) 7/8 (88%) 
Sangalli, 2001 (32) 10/17 (59%) 
40% in MALT (4/10) vs 86% (6/7) in large B cells lymphomas
TABLE 3 - ANN ARBOR CLASSIFICATION OF PTL.
Stage Disease localization
IE Only thyroid
IIE Thyroid and cervical lymph nodes
IIIE Thyroid and lymph nodes above and below diaphragm
IV Thyroid and extension to extranodal sites
compared to radio- and/or chemotherapy (46). Radiotherapy is frequently the treatment of choi-
ce for stages IE-IIE; a systematic review of the literature found only three randomized controlled
studies demonstrating that chemo-radiotherapy is the best treatment (47-49). For more advanced
stages (IIIE or IV) therapy of choice is chemotherapy (CHOP – cyclophosphamide, doxorubicin,
vincristin, prednisone).
Prognosis is related to lymphoma extension: 5-year survival rates are 55-80% for tumors con-
fined to the gland (IE), 20-50% for lesions with extracapsular invasion (IIE); for stages IIIE and
IV the rates are 15-35% (4, 13, 14, 34, 39, 42, 50). Surgery for palliation is rarely indicated: in
such case treatment consists of debulking and tracheostomy carried out for tracheal invasion.
On the basis or the scant and controverse clinical evidence present in the literature we can af-
firm that PTLs require accurate multidisciplinary approach (51), in order to choose the most ap-
propriate therapy case by case.
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